Published online Oct 14, 2020. doi: 10.3748/wjg.v26.i38.5822
Peer-review started: May 26, 2020
First decision: July 29, 2020
Revised: August 8, 2020
Accepted: August 26, 2020
Article in press: August 26, 2020
Published online: October 14, 2020
Processing time: 140 Days and 22.3 Hours
Gastric cancer is a digestive malignancy with high incidence and mortality globally. Despite therapeutic improvement, it remains a leading cause of cancer-associated deaths. Gastric cancer can be diagnosed early by endoscopy and treated by timely surgical excision, but the patient’s long-term survival is still threatened by high metastasis, recurrence, and drug resistance. Active medicinal compounds from natural sources have provided alternative treatment options.
Gastric cancer is a global health threat. Cyclooxygenase (COX)-2 plays an important role in the carcinogenesis and progression of gastric cancer. The effects of acetyl-11-keto-β-boswellic acid (AKBA) on human gastric cancer remain unclear.
The objective of this study was to evaluate the anti-tumor effects and mechanisms of AKBA in human gastric cancer both in vitro and in vivo.
Human gastric cancer cell lines BGC823 and SGC7901 were routinely cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum. Sub-confluent cell cultures were treated with AKBA at a final concentration of 10-50 μM for 24, 48, and 72 h, and the cell proliferation was determined using methyl thiazolyl tetrazolium colorimetric assay. Apoptosis was assessed via flow cytometry analysis. The wound healing assay was performed to evaluate the effects of AKBA on the migration of gastric cancer cells. The expression of proliferating cell nuclear antigen (PCNA), COX-2, Bcl-2, Bax, phosphatase and tensin homolog (PTEN), Akt, and phosphorylated Akt was detected by Western blot analysis. A xenograft nude mouse model of human gastric cancer was established to evaluate the anti-cancer effect of AKBA in vivo.
AKBA significantly inhibited cellular proliferation and migration and induced apoptosis in vitro, as well as inhibited tumor growth in vivo. Additionally, AKBA significantly inhibited the expression of PCNA, COX-2, Bcl-2, and phosphorylated Akt as well as increased PTEN and Bax expression in gastric cancer cells.
AKBA could prevent the development of gastric cancer through the PTEN/Akt/COX-2 signaling pathway.
COX-2 is involved in the carcinogenesis and development of gastric cancer. AKBA is a promising drug for gastric cancer therapy.